-Oleoyl Glycerol is a GPR119 Agonist and Signals GLP-1 Release in Humans.
NCT ID: NCT01043445
Last Updated: 2014-10-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
8 participants
INTERVENTIONAL
2009-09-30
2010-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Diet Oil Induced Stimulation of GLP-1
NCT01453842
Atropin and Glucose Stimulated Insulinsecretion and the Cephalic Insulin Response
NCT01534442
The Effect of GLP-1 on the Inhibition of Glucagon Secretion
NCT01507597
Blocking of the Gut Hormone Receptor for Glucagon-like Peptide 2 (GLP-2) by the GLP-2 Receptor Antagonist GLP-2(3-33)
NCT06774807
Endothelial and Metabolic Effects of Glucagon-like Peptide-1 (GLP-1) in Coronary Circulation in Patients With Type 2 Diabetes Mellitus
NCT00923962
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GPR119 agonist, 2-oleoyl glycerol
2-oleoyl glycerol; 2g. and vehicle
GPR 119 agonist, 2-oleyl glycerol
Emulgation, 50 ml. containing 2g 2OG
Vehicle
Fifty milliliters of glycerol (Sigma-Aldrich; batch 32296AK, purity 99%) plus 5 ml 96% ethanol
Oleic acid
oleic acid; 3.2g and vehicle
Oleic acid
Emulgation, 50 ml. containing 1.54g of oleic acid
Vehicle
Fifty milliliters of glycerol (Sigma-Aldrich; batch 32296AK, purity 99%) plus 5 ml 96% ethanol
Vehicle
5 ml. of glycerol and 5 ml 96% ethanol
Vehicle
Fifty milliliters of glycerol (Sigma-Aldrich; batch 32296AK, purity 99%) plus 5 ml 96% ethanol
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GPR 119 agonist, 2-oleyl glycerol
Emulgation, 50 ml. containing 2g 2OG
Oleic acid
Emulgation, 50 ml. containing 1.54g of oleic acid
Vehicle
Fifty milliliters of glycerol (Sigma-Aldrich; batch 32296AK, purity 99%) plus 5 ml 96% ethanol
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Normal hemoglobin
* Informed consent
Exclusion Criteria
* Nephropathy (s-creatinin \>130 microM or albuminuria)
* Relatives with type 2 diabetes
18 Years
30 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Copenhagen
OTHER
Glostrup University Hospital, Copenhagen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Katrine Bagge Hansen
MD, Ph.d
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Katrine B Hansen, MD
Role: PRINCIPAL_INVESTIGATOR
Glostrup Hospital, University of Copenhagen
Filip K Knop, MD, Ph.d
Role: STUDY_DIRECTOR
Gentofte Hospital
Harald S Hansen, professor
Role: STUDY_DIRECTOR
Farmaceutical Faculty, University of Copenhagen
Jens J Holst, MD;DMSc
Role: STUDY_DIRECTOR
Biomedical Science, University of Copenhagen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Clinical Physiology, Glostrup Hospital
Glostrup Municipality, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GPR119
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.